Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Exploring Actinomycetes-derived natural products for activity against Streptococcus suis

  • Perez Falcón, Ayelén
  • Iorio, Marianna
  • Sosio, Margherita
  • Correa-Fiz, Florencia
  • Donadio, Stefano
  • Aragon, Virginia
Background Streptococcus suis is a major swine pathogen and an emerging zoonotic agent capable of causing severe systemic infections, leading to significant health and economic losses. In recent years, antimicrobial resistance in S. suis has increased substantially, with frequent reports of multidrug-resistant strains driven by extensive antimicrobial use in pig production. This situation is further exacerbated by the role of S. suis as a reservoir of resistance genes within a One Health context. Consequently, there is a growing need for new antimicrobial compounds. Actinomycetes represent a well-known source of bioactive compounds, and the exploration of rare and underexplored taxa offers opportunities to discover novel molecules with unique mechanisms of action. Methods A screening of 800 extracts derived from Actinomycetes was performed against two virulent S. suis strains to evaluate antimicrobial activity. Extracts showing inhibitory effects were further subjected to fractionation by chromatography to isolate and characterize active components. Subsequent analyses focused on identifying fractions with inhibitory activity against the target strains using high-resolution mass spectrometry. Results The initial screening identified numerous Actinomycetes-derived extracts with inhibitory activity against S. suis, including extracts with activity against one or both strains. Based on activity spectrum and taxonomic origin, nine extracts were selected for further analysis. Fractionation enabled the identification of active fractions with consistent inhibitory effects against both strains. Compound characterization revealed bioactive molecules related to verucopeptin, hydroxyrifamycin and thiopeptides. In one extract, the active compound could not be identified, with analysis suggesting a complex composition of its active fraction. Conclusions These findings support Actinomycetes as a valuable source of novel antimicrobials against S. suis. The identified bioactive molecules further emphasize the potential of underexplored microbes for the discovery and development of novel antimicrobials, especially relevant in the context of increasing antimicrobial resistance., This research and APF were funded by the European Union’s Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie Grant Agreement number 956154, as part of the Innovative Training Network (Innovative Approaches to Identification of Metabolic Targets for Antimicrobials [INNOTARGETS]) (https://cordis.europa.eu/project/id/956154). Extracts used for the screening were prepared under Grant Agreement no. 101000392 (MARBLES) funded by the European Union’s Horizon 2020 research and innovation Program, info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Biosynthetic potential of the global ocean microbiome

  • Paoli, Lucas
  • Ruscheweyh, Hans-Joachim
  • Forneris, Clarissa C.
  • Hubrich, Florian
  • Kautsar, Satria
  • Bhushan, Agneya
  • Lotti, Alessandro
  • Clayssen, Quentin
  • Salazar, Guillem
  • Milanese, Alessio
  • Carlström, Charlotte I.
  • Papadopoulou, Chrysa
  • Gehrig, Daniel
  • Karasikov, Mikhaill
  • Mustafa, Harun
  • Larralde, Martin
  • Carroll, Laura M.
  • Sánchez Fernández, Pablo
  • Zayed, Ahmed A.
  • Cronin, Dylan R.
  • Acinas, Silvia G.
  • Bork, Peer
  • Bowler, Chris
  • Delmont, Tom O.
  • Gasol, Josep M.
  • Gossert, Alvar D.
  • Kahles, André
  • Sullivan, Matthew B.
  • Wincker, Patrick
  • Zeller, Georg
  • Robinson, Serina L.
  • Piel, Jörn
  • Sunagawa, Shinichi
8 pages, 4 figures, supplementary information https://doi.org/10.1038/s41586-022-04862-3.-- This Article is contribution number 130 of Tara Oceans, Natural microbial communities are phylogenetically and metabolically diverse. In addition to underexplored organismal groups1, this diversity encompasses a rich discovery potential for ecologically and biotechnologically relevant enzymes and biochemical compounds2,3. However, studying this diversity to identify genomic pathways for the synthesis of such compounds4 and assigning them to their respective hosts remains challenging. The biosynthetic potential of microorganisms in the open ocean remains largely uncharted owing to limitations in the analysis of genome-resolved data at the global scale. Here we investigated the diversity and novelty of biosynthetic gene clusters in the ocean by integrating around 10,000 microbial genomes from cultivated and single cells with more than 25,000 newly reconstructed draft genomes from more than 1,000 seawater samples. These efforts revealed approximately 40,000 putative mostly new biosynthetic gene clusters, several of which were found in previously unsuspected phylogenetic groups. Among these groups, we identified a lineage rich in biosynthetic gene clusters (‘Candidatus Eudoremicrobiaceae’) that belongs to an uncultivated bacterial phylum and includes some of the most biosynthetically diverse microorganisms in this environment. From these, we characterized the phospeptin and pythonamide pathways, revealing cases of unusual bioactive compound structure and enzymology, respectively. Together, this research demonstrates how microbiomics-driven strategies can enable the investigation of previously undescribed enzymes and natural products in underexplored microbial groups and environments, This work was supported by funding from the ETH and the Helmut Horten Foundation; the Swiss National Science Foundation (SNSF) through project grants 205321_184955 to S.S., 205320_185077 to J.P. and the NCCR Microbiomes (51NF40_180575) to S.S.; by the Gordon and Betty Moore Foundation (https://doi.org/10.37807/GBMF9204) and the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 101000392 (MARBLES) to J.P.; by an ETH research grant ETH-21 18-2 to J.P.; and by the Peter and Traudl Engelhorn Foundation and by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 897571 to C.C.F. S.L.R. was supported by an ETH Zurich postdoctoral fellowship 20-1 FEL-07. M.L., L.M.C. and G.Z. were supported by EMBL Core Funding and the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft, project no. 395357507, SFB 1371 to G.Z.). M.B.S. was supported by the NSF grant OCE#1829831. C.B. was supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement Diatomic, no. 835067). S.G.A. was supported by the Spanish Ministry of Economy and Competitiveness (PID2020-116489RB-I00). M.K. and H.M. were funded by the SNSF grant 407540_167331 as part of the Swiss National Research Programme 75 ‘Big Data’. M.K., H.M. and A.K. are also partially funded by ETH core funding (to G. Rätsch), With the institutional support of the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000928-S), Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Exploring Actinomycetes-derived natural products for activity against Streptococcus suis

  • Perez Falcón, Ayelén
  • Iorio, Marianna
  • Sosio, Margherita
  • Correa-Fiz, Florencia
  • Donadio, Stefano
  • Aragon, Virginia
Background Streptococcus suis is a major swine pathogen and an emerging zoonotic agent capable of causing severe systemic infections, leading to significant health and economic losses. In recent years, antimicrobial resistance in S. suis has increased substantially, with frequent reports of multidrug-resistant strains driven by extensive antimicrobial use in pig production. This situation is further exacerbated by the role of S. suis as a reservoir of resistance genes within a One Health context. Consequently, there is a growing need for new antimicrobial compounds. Actinomycetes represent a well-known source of bioactive compounds, and the exploration of rare and underexplored taxa offers opportunities to discover novel molecules with unique mechanisms of action. Methods A screening of 800 extracts derived from Actinomycetes was performed against two virulent S. suis strains to evaluate antimicrobial activity. Extracts showing inhibitory effects were further subjected to fractionation by chromatography to isolate and characterize active components. Subsequent analyses focused on identifying fractions with inhibitory activity against the target strains using high-resolution mass spectrometry. Results The initial screening identified numerous Actinomycetes-derived extracts with inhibitory activity against S. suis, including extracts with activity against one or both strains. Based on activity spectrum and taxonomic origin, nine extracts were selected for further analysis. Fractionation enabled the identification of active fractions with consistent inhibitory effects against both strains. Compound characterization revealed bioactive molecules related to verucopeptin, hydroxyrifamycin and thiopeptides. In one extract, the active compound could not be identified, with analysis suggesting a complex composition of its active fraction. Conclusions These findings support Actinomycetes as a valuable source of novel antimicrobials against S. suis. The identified bioactive molecules further emphasize the potential of underexplored microbes for the discovery and development of novel antimicrobials, especially relevant in the context of increasing antimicrobial resistance., This research and APF were funded by the European Union’s Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie Grant Agreement number 956154, as part of the Innovative Training Network (Innovative Approaches to Identification of Metabolic Targets for Antimicrobials [INNOTARGETS]) (https://cordis.europa.eu/project/id/956154). Extracts used for the screening were prepared under Grant Agreement no. 101000392 (MARBLES) funded by the European Union’s Horizon 2020 research and innovation Program, info:eu-repo/semantics/publishedVersion